A registrational clinical trial for VRDN-002
Latest Information Update: 06 Apr 2022
At a glance
- Drugs VRDN 002 (Primary)
- Indications Graves ophthalmopathy
- Focus Registrational; Therapeutic Use
- Sponsors Viridian Therapeutics
Most Recent Events
- 06 Apr 2022 New trial record